Cotation du 26/05/2017 à 22h30

ANTARES PHARMA -1,57% 2,51$

  •   PEA
  •   PEA-PME
  • ATRS - US0366421065
  • + Ajouter à : Mes Listes

Objectif de cours au 28/05/2017

4,360 €
Potentiel de +74%
cours actuel 2,510$

Note médiane des 4 analystes

1,3
5 Vendre 4 Alléger 3 Conserver 2 Renforcer 1 Acheter
Conseil des analystes au Acheter

Evolution des recommandations

Recommandations 28/05/2016 28/08/2016 28/11/2016 28/02/2017 28/05/2017
Acheter 2 2 2 2 3
Renforcer 1 1 1 1 1
Conserver - - - - -
Alléger - - - - -
Vendre - - - - -
Nb d'analystes 3 3 3 3 4
Note Médiane 1,33 1,33 1,33 1,33 1,25
Historique des objectifs 3,000$ 2,667$ 2,825$ 3,075$ 4,360$

Prévisions

2016 2017 2018
Chiffre d'affaires 52,22 54,72 102,13
EBITDA - - -
EBIT - - -
Résultat Net -24,34 -19,98 4,10
Flux de trésorerie disponible - - -
Dette nette - - -
PER -15,69 -20,49 111,56
Copyright © 2016, S&P Global Market Intelligence. Reproduction of CIQ Estimates in any form is prohibited except with the prior written permission of S&P Global Market Intelligence. CIQ Estimates are not investment advice and a reference to a particular investment or security, a credit rating or any observation concerning a security or investment provided in CIQ Estimates is not a recommendation to buy, sell or hold such investment or security or make any other investment decisions. S&P Global Market Intelligence, its affiliates and their third-party providers (together, “S&P Global”) do not guarantee the accuracy, adequacy, completeness or availability of any information and are not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P GLOBAL DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P Global be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of CIQ Estimates.